Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MARS1 | P56192 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2033721 | 0.81 | AHR (0.40) | CYP19A1MAPTSCN4ANPC1RAB9A | |
| SCHEMBL5214295 | 0.80 | AURKA (0.45) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL5390819 | 0.77 | MAPK14 (0.45) | DHODHMAPTNPC1RAB9AMEN1 | |
| SCHEMBL4872294 | 0.77 | HRH3 (0.49) | CYP19A1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL23998385 | 0.74 | CYP19A1 (0.41) | DHODHCYP19A1MAPTSCN4ANPC1 | |
| SCHEMBL2030860 | 0.74 | KMT2A (0.41) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL31692761 | 0.74 | CYP19A1 (0.44) | CYP19A1MEN1KMT2ATDP2MARS1 | |
| SCHEMBL2035074 | 0.71 | PI4KB (0.40) | SCN4ASMN1; SMN2TDP2 | |
| SCHEMBL10475879 | 0.71 | NR4A2 (0.37) | DHODHNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2029895 | 0.71 | LIPG (0.51) | CYP19A1MAPTSCN4ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423389-B1 | PYRAZOLO-PYRIDINES FOR THE TREATMENT OF HERPES INFECTIONS | SMITHKLINE BEECHAM CORP (US) | 2007-06-06 | — | — | EP | disclosed |
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-7030134-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | ALBERTI MICHAEL J | 2006-03-16 | — | — | US | disclosed |
| US-6962914-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050192303-A1 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | GUDMUNDSSON KRISTJAN (US) | 2005-09-01 | — | — | US | disclosed |
| EP-1341788-B1 | PYRAZOLOPYRIDINES | GLAXO GROUP LTD (GB) | 2005-08-10 | — | — | EP | disclosed |
| US-6919352-B2 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1385847-B1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20040142941-A1 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2004-07-22 | — | — | US | disclosed |
| US-20040072853-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY D (US) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142941-A1 | Therapeutic compounds | PCSK9, ABCB1, ABCB11 | DHODH 1073/4885CYP19A1 352/4885MAPT 712/4885 |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | CYP3A5, CYP3A4, CYP3A7 | DHODH 386/4885CYP19A1 1250/4885MAPT 2152/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | DHODH 452/4885CYP19A1 4592/4885MAPT 3435/4885 |
| US-20040072853-A1 | Therapeutic compounds | PCSK9, ABCB1, FURIN | DHODH 943/4885CYP19A1 231/4885MAPT 797/4885 |
| US-20050192303-A1 | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds | DPYD, TYMP, P2RY4 | DHODH 154/4885CYP19A1 1000/4885MAPT 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.